Canaccord analyst John Newman raised the firm’s price target on Atara Biotherapeutics (ATRA) to $21 from $13 and keeps a Buy rating on the shares. The firm said its target increase is based on its expectations for positive ATA3219 data in NHL and Lupus in early 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA: